Prostate cancer
Research activity is centered on prostate cancer, with particular interest in treatment personalisation and disease control in men receiving radiotherapy.
- Radiotherapy
- Androgen deprivation therapy
- Disease-free survival
The sponsor is involved in clinical work that examines how treatment intensity and duration can be adapted for patients with prostate cancer.
Image-guided treatment selection
Another area of interest is the use of PSMA PET/CT imaging to support treatment planning in prostate cancer, linking diagnostic imaging with therapeutic decision-making.
- PSMA PET/CT
- Positron emission tomography
- Computed tomography
This focus reflects work on aligning imaging findings with radiotherapy design and patient-specific management.
Artificial intelligence in oncology
The sponsor also engages in the application of artificial intelligence to oncology, using computational support to inform personalised treatment strategies.
- Multimodal artificial intelligence
- Personalised medicine
- Clinical decision support
Interest in AI-driven methods is directed toward refining radiotherapy and hormonal treatment choices for patients with prostate cancer.
Hypofractionated radiotherapy
Clinical research includes ultra-hypofractionated radiotherapy and dose escalation approaches for localised treatment of prostate cancer.
- Ultra-hypofractionation
- Dose escalation
- Local tumour control
These topics are tied to efforts to streamline treatment delivery while maintaining oncologic effectiveness.
Treatment duration and patient convenience
Research interest extends to reducing the overall length of treatment and simplifying care pathways for patients undergoing therapy for prostate cancer.
- Treatment de-intensification
- Shortened therapy schedules
- Patient convenience
This includes work on combining shorter radiotherapy courses with adjusted hormonal therapy in the management of prostate cancer.
